REHOVOT, Israel – March 15, 2022 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer. March 15th, 2022 Dear Shareholders, Colleagues and Business Partners: The recently completed 2021 year was a transformational period […]
New Executives to Strengthen the Company’s U.S. Commercial Operations, Focused on Recently Acquired Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Products, and Planned Opening of New Plasma Collection Centers REHOVOT, Israel – March 14, 2022 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced the […]
Rehovot, Israel, March 2, 2022 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial markets on Tuesday, March 15, 2022. Kamada management will host an investment community […]
2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada, Respectively. Acquisition Advances Kamada’s Strategy of Evolving Into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S.; Kamada’s Wholly-Owned U.S. Subsidiary, Kamada […]
Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 Million Kamada has Acquired a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics; Transaction Supports Kamada’s Strategy of Evolving into a Fully-Integrated Specialty Plasma Company with Strong Commercial Capabilities in the U.S. and […]
Rehovot, Israel, November 8, 2021 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and nine months ended September 30, 2021, prior to the open of the U.S. financial markets on Monday, November 22, 2021. Kamada management will host an investment community […]
Second Quarter 2021 Revenues were $24.2 Million In Connection with the Transition of GLASSIA® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an Approximately 10% Annual Labor Cost Reduction Pivotal Phase 3 InnovAATe Trial for Inhaled AAT for Treatment of Alpha-1 Antitrypsin Deficiency Continues to Advance as […]
Rehovot, Israel, August 5, 2021 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on Wednesday, August 11, 2021. Kamada management will host an investment community […]
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in Children KEDRAB Product Label Now Includes Patients of All Ages New FDA Approval Based on Safety […]
First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 Million In Connection with the Transition of GLASSIA® Manufacturing, the Product’s U.S. Biologics License Application will be Transferred to Takeda by the End of 2021 and Kamada will Receive a Payment of $2 Million; Kamada to Implement a Workforce Downsizing During Early Q3 […]